{"id":"cisplatin-carboplatin-gemcitabine-cindilimab","safety":{"commonSideEffects":[{"rate":null,"effect":"Myelosuppression (neutropenia, thrombocytopenia, anemia)"},{"rate":null,"effect":"Nausea and vomiting"},{"rate":null,"effect":"Nephrotoxicity"},{"rate":null,"effect":"Neuropathy"},{"rate":null,"effect":"Immune-related adverse events (from cindilimab)"}]},"_chembl":{"chemblId":"CHEMBL1351","moleculeType":"Small molecule","molecularWeight":"371.25"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cisplatin and carboplatin are platinum compounds that cross-link DNA and induce apoptosis in rapidly dividing cells. Gemcitabine is a deoxycytidine analog that inhibits ribonucleotide reductase and gets incorporated into DNA, causing chain termination. Cindilimab is a PD-L1 inhibitor that blocks the interaction between PD-L1 on tumor cells and PD-1 on T cells, thereby restoring anti-tumor immune responses.","oneSentence":"This is a combination regimen of platinum-based chemotherapy agents (cisplatin/carboplatin) and a nucleoside analog (gemcitabine), plus an anti-PD-L1 monoclonal antibody (cindilimab) that together kill cancer cells through DNA damage and immune checkpoint inhibition.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:30:04.548Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"},{"name":"Other solid tumors (specific indications not fully characterized in available literature)"}]},"trialDetails":[{"nctId":"NCT05312840","phase":"PHASE4","title":"Efficacy and Safety of Conventional and Low-dose Platinum Gemcitabine Combined With Cindilimab With Delayed Administration in First-line Treatment of Advanced Squamous Non-small Cell Lung Cancer","status":"UNKNOWN","sponsor":"People's Hospital of Quzhou","startDate":"2022-01-01","conditions":"Non Small Cell Lung Cancer","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Cisplatin / Carboplatin，Gemcitabine，Cindilimab","genericName":"Cisplatin / Carboplatin，Gemcitabine，Cindilimab","companyName":"People's Hospital of Quzhou","companyId":"people-s-hospital-of-quzhou","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This is a combination regimen of platinum-based chemotherapy agents (cisplatin/carboplatin) and a nucleoside analog (gemcitabine), plus an anti-PD-L1 monoclonal antibody (cindilimab) that together kill cancer cells through DNA damage and immune checkpoint inhibition. Used for Non-small cell lung cancer, Other solid tumors (specific indications not fully characterized in available literature).","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}